A phase IIB, randomized, double-blinded, placebo-controlled study of low dose cytarabine and lintuzumab compared to low dose cytarabine and placebo in patients 60 years of age and older with previously untreated AML

Trial Profile

A phase IIB, randomized, double-blinded, placebo-controlled study of low dose cytarabine and lintuzumab compared to low dose cytarabine and placebo in patients 60 years of age and older with previously untreated AML

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs Lintuzumab (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 16 Jul 2012 Results published in Haematologica.
    • 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 20 Sep 2010 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top